Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes

Authors: Zhihui Wang, Claes G Trope, Vivi Ann Flørenes, Zhenhe Suo, Jahn M Nesland, Ruth Holm

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

CDC25 phosphatases are important regulators of the cell cycle. Their abnormal expression detected in a number of tumors implies that their dysregulation is involved in malignant transformation. However, the role of CDC25s in vulvar cancer is still unknown. To shed light on their roles in the pathogenesis and to clarify their prognostic values, expression of CDC25A, CDC25B and CDC25C in a large series of vulvar squamous cell carcinomas were examined.

Methods

Expression of CDC25A, CDC25B, CDC25C and phosphorylated (phospho)-CDC25C (Ser216) were examined in 300 vulvar carcinomas using immunohistochemistry. Western blot analysis was utilized to demonstrate CDC25s expression in vulvar cancer cell lines. Kinase and phosphatase assays were performed to exclude cross reactivity among CDC25s isoform antibodies.

Results

High nuclear CDC25A and CDC25B expression were observed in 51% and 16% of the vulvar carcinomas, respectively, whereas high cytoplasmic CDC25C expression was seen in 63% of the cases. In cytoplasm, nucleus and cytoplasm/nucleus high phospho-CDC25C (Ser216) expression was identified in 50%, 70% and 77% of the carcinomas, respectively. High expression of CDC25s correlated significantly with malignant features, including poor differentiation and infiltration of vessel for CDC25B, high FIGO stage, presence of lymph node metastases, large tumor diameter, poor differentiation for CDC25C and high FIGO stage, large tumor diameter, deep invasion and poor differentiation for phospho-CDC25C (Ser216). In univariate analysis, high expression of phospho-CDC25C (Ser216) was correlated with poor disease-specific survival (p = 0.04). However, such an association was annulled in multivariate analysis.

Conclusions

Our results suggest that CDC25C and phospho-CDC25C (Ser216) play a crucial role and CDC25B a minor role in the pathogenesis and/or progression of vulvar carcinomas. CDC25B, CDC25C and phospho-CDC25C (Ser216) were associated with malignant features and aggressive cancer phenotypes. However, the CDC25s isoforms were not independently correlated to prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coulter J, Gleeson N: Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol. 2003, 17: 663-681. 10.1016/S1521-6934(03)00050-6.CrossRefPubMed Coulter J, Gleeson N: Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol. 2003, 17: 663-681. 10.1016/S1521-6934(03)00050-6.CrossRefPubMed
2.
go back to reference Jones RW, Baranyai J, Stables S: Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997, 90: 448-452. 10.1016/S0029-7844(97)00298-6.CrossRefPubMed Jones RW, Baranyai J, Stables S: Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997, 90: 448-452. 10.1016/S0029-7844(97)00298-6.CrossRefPubMed
3.
go back to reference Messing MJ, Gallup DG: Carcinoma of the vulva in young women. Obstet Gynecol. 1995, 86: 51-54. 10.1016/0029-7844(95)00101-V.CrossRefPubMed Messing MJ, Gallup DG: Carcinoma of the vulva in young women. Obstet Gynecol. 1995, 86: 51-54. 10.1016/0029-7844(95)00101-V.CrossRefPubMed
4.
go back to reference Tyring SK: Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol. 2003, 189: S17-S23. 10.1067/S0002-9378(03)00792-0.CrossRefPubMed Tyring SK: Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol. 2003, 189: S17-S23. 10.1067/S0002-9378(03)00792-0.CrossRefPubMed
5.
go back to reference Boutros R, Lobjois V, Ducommun B: CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer. 2007, 7: 495-507. 10.1038/nrc2169.CrossRefPubMed Boutros R, Lobjois V, Ducommun B: CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer. 2007, 7: 495-507. 10.1038/nrc2169.CrossRefPubMed
6.
go back to reference Kristjansdottir K, Rudolph J: Cdc25 phosphatases and cancer. Chem Biol. 2004, 11: 1043-1051. 10.1016/j.chembiol.2004.07.007.CrossRefPubMed Kristjansdottir K, Rudolph J: Cdc25 phosphatases and cancer. Chem Biol. 2004, 11: 1043-1051. 10.1016/j.chembiol.2004.07.007.CrossRefPubMed
7.
go back to reference Aressy B, Ducommun B: Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem. 2008, 8: 818-824.CrossRefPubMed Aressy B, Ducommun B: Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem. 2008, 8: 818-824.CrossRefPubMed
8.
go back to reference Sasaki H, Yukiue H, Kobayashi Y, Tanahashi M, Moriyama S, Nakashima Y, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y: Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett. 2001, 173: 187-192. 10.1016/S0304-3835(01)00669-3.CrossRefPubMed Sasaki H, Yukiue H, Kobayashi Y, Tanahashi M, Moriyama S, Nakashima Y, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y: Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett. 2001, 173: 187-192. 10.1016/S0304-3835(01)00669-3.CrossRefPubMed
9.
go back to reference Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, Matsumoto T, Aihara T, Tomita N, Tamaki Y, Sakita I, Kikkawa N, Matsuura N, Shiozaki H, Monden M: Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res. 2000, 60: 3043-3050.PubMed Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, Matsumoto T, Aihara T, Tomita N, Tamaki Y, Sakita I, Kikkawa N, Matsuura N, Shiozaki H, Monden M: Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res. 2000, 60: 3043-3050.PubMed
10.
go back to reference Tsuda H, Hashiguchi Y, Inoue T, Yamamoto K: Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology. 2003, 65: 159-166. 10.1159/000072342.CrossRefPubMed Tsuda H, Hashiguchi Y, Inoue T, Yamamoto K: Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology. 2003, 65: 159-166. 10.1159/000072342.CrossRefPubMed
11.
go back to reference Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D: CDC25 phosphatases as potential human oncogenes. Science. 1995, 269: 1575-1577. 10.1126/science.7667636.CrossRefPubMed Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D: CDC25 phosphatases as potential human oncogenes. Science. 1995, 269: 1575-1577. 10.1126/science.7667636.CrossRefPubMed
12.
go back to reference Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Ranashinge M, Cady B, Pagano M, Loda M: Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000, 106: 753-761. 10.1172/JCI9174.CrossRefPubMedPubMedCentral Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Ranashinge M, Cady B, Pagano M, Loda M: Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000, 106: 753-761. 10.1172/JCI9174.CrossRefPubMedPubMedCentral
13.
go back to reference Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C, D'Incalci M: Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 2000, 20: 4835-4840.PubMed Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C, D'Incalci M: Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 2000, 20: 4835-4840.PubMed
14.
go back to reference Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, Fujiwara Y, Yano M, Miyata H, Kishi K, Nakagawa H, Shamma A, Monden M: Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Cancer. 2001, 85: 412-421. 10.1054/bjoc.2001.1934.CrossRefPubMedPubMedCentral Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, Fujiwara Y, Yano M, Miyata H, Kishi K, Nakagawa H, Shamma A, Monden M: Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Cancer. 2001, 85: 412-421. 10.1054/bjoc.2001.1934.CrossRefPubMedPubMedCentral
15.
go back to reference Ozen M, Ittmann M: Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res. 2005, 11: 4701-4706. 10.1158/1078-0432.CCR-04-2551.CrossRefPubMed Ozen M, Ittmann M: Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res. 2005, 11: 4701-4706. 10.1158/1078-0432.CCR-04-2551.CrossRefPubMed
16.
go back to reference Shepherd JH: Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol. 1996, 103: 405-406.CrossRefPubMed Shepherd JH: Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol. 1996, 103: 405-406.CrossRefPubMed
17.
go back to reference WHO: Pathology and Genetics: Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumors. 2003, Lyon: IARC Press, 316-321. WHO: Pathology and Genetics: Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumors. 2003, Lyon: IARC Press, 316-321.
18.
go back to reference Knopp S, Nesland JM, Trope C, Holm R: p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol. 2006, 126: 266-276. 10.1309/E9E8Y9WG5QE3LK29.CrossRefPubMed Knopp S, Nesland JM, Trope C, Holm R: p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol. 2006, 126: 266-276. 10.1309/E9E8Y9WG5QE3LK29.CrossRefPubMed
19.
go back to reference Wang Z, Trope CG, Suo Z, Troen G, Yang G, Nesland JM, Holm R: The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer. 2008, 8: 308-10.1186/1471-2407-8-308.CrossRefPubMedPubMedCentral Wang Z, Trope CG, Suo Z, Troen G, Yang G, Nesland JM, Holm R: The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer. 2008, 8: 308-10.1186/1471-2407-8-308.CrossRefPubMedPubMedCentral
20.
go back to reference Jorgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Florenes VA: Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochem Biophys Res Commun. 2005, 329: 266-274. 10.1016/j.bbrc.2005.01.143.CrossRefPubMed Jorgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Florenes VA: Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochem Biophys Res Commun. 2005, 329: 266-274. 10.1016/j.bbrc.2005.01.143.CrossRefPubMed
21.
go back to reference Xu X, Yamamoto H, Sakon M, Yasui M, Ngan CY, Fukunaga H, Morita T, Ogawa M, Nagano H, Nakamori S, Sekimoto M, Matsuura N, Monden M: Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res. 2003, 9: 1764-1772.PubMed Xu X, Yamamoto H, Sakon M, Yasui M, Ngan CY, Fukunaga H, Morita T, Ogawa M, Nagano H, Nakamori S, Sekimoto M, Matsuura N, Monden M: Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res. 2003, 9: 1764-1772.PubMed
22.
go back to reference Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A: Expression of cdc25A and cdc25B proteins in thyroid neoplasms. Br J Cancer. 2002, 86: 1909-1913. 10.1038/sj.bjc.6600364.CrossRefPubMedPubMedCentral Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A: Expression of cdc25A and cdc25B proteins in thyroid neoplasms. Br J Cancer. 2002, 86: 1909-1913. 10.1038/sj.bjc.6600364.CrossRefPubMedPubMedCentral
23.
go back to reference Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY: Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene. 2003, 22: 734-739. 10.1038/sj.onc.1206121.CrossRefPubMed Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY: Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene. 2003, 22: 734-739. 10.1038/sj.onc.1206121.CrossRefPubMed
24.
go back to reference Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E: Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res. 1997, 88: 947-952.CrossRefPubMed Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E: Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res. 1997, 88: 947-952.CrossRefPubMed
25.
go back to reference Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, Muntane J, Castells A, Fernandez PL, Cardesa A, Campo E: Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. 2001, 81: 465-473.CrossRefPubMed Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, Muntane J, Castells A, Fernandez PL, Cardesa A, Campo E: Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. 2001, 81: 465-473.CrossRefPubMed
26.
go back to reference Miyata H, Doki Y, Shiozaki H, Inoue M, Yano M, Fujiwara Y, Yamamoto H, Nishioka K, Kishi K, Monden M: CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000, 6: 4859-4865.PubMed Miyata H, Doki Y, Shiozaki H, Inoue M, Yano M, Fujiwara Y, Yamamoto H, Nishioka K, Kishi K, Monden M: CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000, 6: 4859-4865.PubMed
27.
go back to reference Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW, Friess H: Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene. 2004, 23: 71-81. 10.1038/sj.onc.1206926.CrossRefPubMed Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW, Friess H: Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene. 2004, 23: 71-81. 10.1038/sj.onc.1206926.CrossRefPubMed
28.
go back to reference Dalal SN, Yaffe MB, DeCaprio JA: 14-3-3 family members act coordinately to regulate mitotic progression. Cell Cycle. 2004, 3: 672-677. 10.4161/cc.3.5.856.CrossRefPubMed Dalal SN, Yaffe MB, DeCaprio JA: 14-3-3 family members act coordinately to regulate mitotic progression. Cell Cycle. 2004, 3: 672-677. 10.4161/cc.3.5.856.CrossRefPubMed
29.
go back to reference Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, Lukas J: Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 2002, 21: 5911-5920. 10.1093/emboj/cdf567.CrossRefPubMedPubMedCentral Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, Lukas J: Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 2002, 21: 5911-5920. 10.1093/emboj/cdf567.CrossRefPubMedPubMedCentral
30.
go back to reference Bugler B, Quaranta M, Aressy B, Brezak MC, Prevost G, Ducommun B: Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther. 2006, 5: 1446-1451. 10.1158/1535-7163.MCT-06-0099.CrossRefPubMed Bugler B, Quaranta M, Aressy B, Brezak MC, Prevost G, Ducommun B: Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther. 2006, 5: 1446-1451. 10.1158/1535-7163.MCT-06-0099.CrossRefPubMed
31.
go back to reference Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J: Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999, 146: 573-584. 10.1083/jcb.146.3.573.CrossRefPubMedPubMedCentral Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J: Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol. 1999, 146: 573-584. 10.1083/jcb.146.3.573.CrossRefPubMedPubMedCentral
32.
go back to reference Escalas N, Davezac N, De RJ, Baldin V, Mazars R, Ducommun B: Study of the cytolethal distending toxin-induced cell cycle arrest in HeLa cells: involvement of the CDC25 phosphatase. Exp Cell Res. 2000, 257: 206-212. 10.1006/excr.2000.4878.CrossRefPubMed Escalas N, Davezac N, De RJ, Baldin V, Mazars R, Ducommun B: Study of the cytolethal distending toxin-induced cell cycle arrest in HeLa cells: involvement of the CDC25 phosphatase. Exp Cell Res. 2000, 257: 206-212. 10.1006/excr.2000.4878.CrossRefPubMed
33.
go back to reference Bansal P, Lazo JS: Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res. 2007, 67: 3356-3363. 10.1158/0008-5472.CAN-06-3685.CrossRefPubMed Bansal P, Lazo JS: Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res. 2007, 67: 3356-3363. 10.1158/0008-5472.CAN-06-3685.CrossRefPubMed
34.
go back to reference Nagata A, Igarashi M, Jinno S, Suto K, Okayama H: An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol. 1991, 3: 959-968.PubMed Nagata A, Igarashi M, Jinno S, Suto K, Okayama H: An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol. 1991, 3: 959-968.PubMed
35.
go back to reference Spitkovsky D, Jansen-Durr P, Karsenti E, Hoffman I: S-phase induction by adenovirus E1A requires activation of cdc25a tyrosine phosphatase. Oncogene. 1996, 12: 2549-2554.PubMed Spitkovsky D, Jansen-Durr P, Karsenti E, Hoffman I: S-phase induction by adenovirus E1A requires activation of cdc25a tyrosine phosphatase. Oncogene. 1996, 12: 2549-2554.PubMed
36.
37.
go back to reference Hu YC, Lam KY, Law S, Wong J, Srivastava G: Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res. 2001, 7: 2213-2221.PubMed Hu YC, Lam KY, Law S, Wong J, Srivastava G: Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res. 2001, 7: 2213-2221.PubMed
38.
go back to reference Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, Phillips C, Zhao H, Moody SA, Appella E, Piwnica-Worms H, Fornace AJ: Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol. 2003, 5: 545-551. 10.1038/ncb994.CrossRefPubMed Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, Phillips C, Zhao H, Moody SA, Appella E, Piwnica-Worms H, Fornace AJ: Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol. 2003, 5: 545-551. 10.1038/ncb994.CrossRefPubMed
Metadata
Title
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
Authors
Zhihui Wang
Claes G Trope
Vivi Ann Flørenes
Zhenhe Suo
Jahn M Nesland
Ruth Holm
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-233

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine